Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis

NCT02252653 is registered in ClinicalTrials.gov with Alnylam Pharmaceuticals as lead sponsor.

NCT NCT02252653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02252653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
Lead sponsor
Alnylam Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
June 30, 2014
Completion date
March 31, 2016
Enrollment
1,010 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

familial amyloidotic cardiomyopathy (fac)